What the WADA Prohibited List Is, and How to Use It Safely

The World Anti-Doping Agency publishes a new Prohibited List each year. The 2026 List took effect on January 1, 2026. It identifies substances and methods that are banned at all times, only during the in-competition period, or only in particular sports.

That sounds like a searchable blacklist. In practice, safe use requires several linked questions: What is the active ingredient? What route and dose are being used? When is the competition period? Does a class rule capture related compounds that are not named? Is a therapeutic use exemption required? Has the product changed since it was last checked?

The List is therefore a regulatory classification tool.

What makes a substance or method eligible for the List#

Under the World Anti-Doping Code, WADA considers whether a substance or method can enhance performance, presents an actual or potential health risk, or violates the spirit of sport. At least two of those three criteria generally support inclusion. WADA may also prohibit a substance or method that can mask another prohibited item.

This is not the same as a general judgment that a medicine is bad. Many listed medicines have accepted clinical uses. The concern is their use within organized sport under a harmonized anti-doping framework. A medicine can be appropriate for a patient and still require advance authorization for an athlete.

The List is incorporated into the Code system used by signatory organizations. Competition rules, testing authority, results management, and TUE jurisdiction still depend on the athlete's sport and level. Your national anti-doping organization or international federation is the body that resolves case-specific questions.

The three timing categories#

The largest group is prohibited at all times, meaning during and outside competition. It includes anabolic agents, peptide hormones and growth factors, beta-2 agonists subject to listed exceptions and thresholds, hormone and metabolic modulators, diuretics and masking agents, non-approved substances, and prohibited methods.

The in-competition section adds stimulants, narcotics, cannabinoids, and glucocorticoids by prohibited routes, among other classes. The definition of the in-competition period usually begins at 11:59 p.m. on the day before a competition in which the athlete is scheduled to participate and continues through the competition and sample-collection process, unless an approved rule provides another period.

Beta-blockers are prohibited only in listed sports, sometimes both in and out of competition depending on the sport. That narrow category shows why a generic answer such as “allowed for athletes” can be wrong. Sport, timing, and route are part of the answer.

Class rules reach beyond named examples#

The List names many substances but is not limited to them. Phrases such as “including, but not limited to” and “other substances with a similar chemical structure or similar biological effect” extend some classes. A novel compound, compounded product, research chemical, or marketed analogue cannot be treated as permitted merely because your text search returns no exact match.

Category S0 addresses pharmacological substances that are not approved by a governmental regulatory health authority for human therapeutic use; this includes drugs in preclinical or clinical development, discontinued drugs, designer drugs, and substances approved only for veterinary use. S0 applies at all times. The practical rule is conservative: an unsuccessful name search is not clearance, and the athlete or support professional should identify every active ingredient and ask the relevant anti-doping organization when a result is unclear.

Routes and thresholds can change the answer#

Some rules depend on how a medicine enters the body. The same active ingredient may be prohibited by one route but permitted by another. Glucocorticoids illustrate this distinction: certain injectable, oral, and rectal routes are prohibited in competition, while other local routes may not be prohibited under the List. Dose, timing, formulation, and washout guidance still matter.

Some inhaled beta-2 agonists have permitted maximum doses and decision limits. Those details are not a home dosing target and should never displace your asthma plan. They mean that the exact medicine, dose schedule, and clinical record must be checked, because a laboratory finding above a decision limit can require the athlete to establish that the result followed permitted therapeutic use. Intravenous infusions or injections above the listed volume over a 12-hour period are generally prohibited unless legitimately received during hospital treatment, surgery, or clinical diagnostic investigations, so the method rule can matter even when the infused substance is not itself prohibited.

Strict liability and the athlete's responsibility#

The Code's strict-liability principle means that the presence of a prohibited substance or its metabolites or markers can establish a violation without proof that the athlete intended to cheat. Intent can matter greatly to the sanction and other consequences, but it is not normally required to establish presence.

This rule is why verbal reassurance is weak protection. Keep screenshots or reference numbers from an official medicine check, with the date you checked, the product name, the ingredient list, the strength, the route, the dose, the country of purchase, the prescriber documentation, and any TUE decision.

Support personnel also have duties. A prescriber, pharmacist, trainer, or coach should not promise that a product is safe without checking the applicable rules. Stay part of the verification yourself rather than handing responsibility to a single adviser.

A prescription is not a TUE#

A prescription shows that a licensed clinician selected a treatment. A therapeutic use exemption is a formal anti-doping decision permitting use of an otherwise prohibited substance or method under defined conditions.

The International Standard for TUEs sets criteria. In broad terms, the treatment must be needed for a diagnosed medical condition; withholding it must cause significant health impairment; it should not produce performance enhancement beyond return to normal health; and there must be no reasonable permitted alternative. The condition and reasoning need adequate clinical evidence.

Jurisdiction and timing vary. International-level athletes commonly apply through their international federation, while national-level athletes usually use their national anti-doping organization. Some athletes may qualify for retroactive recognition under specified conditions. Approval from the correct body, valid for the relevant dates and conditions, is what matters.

Urgent and emergency treatment comes first#

An emergency can make prior checking impossible. Necessary medical treatment should not be delayed for an anti-doping search. When feasible, tell the clinical team that you are subject to testing, so they can document active ingredients, routes, doses, dates, diagnosis, and alternatives considered.

After stabilization, contact the responsible anti-doping organization promptly. Preserve emergency notes, medication administration records, imaging, laboratory findings, discharge documents, and the treating clinician's explanation: a retroactive TUE is not automatic, but a complete contemporaneous record makes a fair assessment possible. The same documentation principle applies when a prohibited medicine is given without your knowledge while you are incapacitated: medical necessity and anti-doping procedure both still have to be addressed.

How to check a medicine properly#

Global DRO allows searches for medication status in participating countries. Other national organizations operate their own official databases. A reliable check uses the exact active ingredient and product, not only the brand family, because similarly named products can contain different ingredients.

Record the country, because product composition and database coverage vary. Check each ingredient in combination cold, pain, sleep, allergy, and weight-management products, confirm the route, dose, sport, and competition timing, and then repeat the whole check after a refill, a formulation change, travel, a rule update, or a new calendar year.

A database result applies only to the information you entered and the rules loaded on that day. It does not diagnose whether a TUE is clinically justified. Ambiguous, compounded, imported, or non-approved products need direct advice from the relevant anti-doping body.

Why supplements need a separate risk discussion#

Dietary supplements do not pass through the same premarket drug-approval pathway as prescription medicines in many jurisdictions. A label can omit a stimulant, list a misleading synonym, vary by batch, or contain contamination from manufacturing. Products marketed for muscle growth, fat loss, sexual performance, focus, or rapid recovery warrant special caution.

USADA's Supplement Connect explains that no organization can guarantee a supplement is free of prohibited substances. Batch-tested certification programs can lower risk by testing products and auditing processes, but they cannot make risk zero or replace a medical need assessment.

Ask first whether the supplement has a clear purpose, evidence of benefit, and a safer food or permitted-medication alternative. If you go ahead anyway, choose a product from a credible batch-certification program, verify the exact batch, keep the container and the receipt, and document the decision.

Common mistakes that create avoidable risk#

One mistake is checking only once. The List changes annually, and a medicine that was acceptable last season may have new conditions. Another is relying on a teammate, retail employee, influencer, or automated summary. Their answer may use another country's formulation or last year's rules.

A third mistake is assuming topical, injected, inhaled, oral, and rectal versions share one status. A fourth is stopping an essential medicine without clinical advice. That can harm the athlete and may not solve the timing problem.

A final mistake is treating a negative supplement-label search as proof. Anti-doping analysis tests the sample, not the marketing claim. Risk management requires product selection, clinical justification, records, and awareness that residual risk remains.

A practical precompetition medication review#

Create one current list of prescriptions, over-the-counter medicines, supplements, injections, infusions, and compounded products. Include occasional items such as decongestants or sleep aids. For each item, record the active ingredient, dose, route, timing, country, and reason for use.

Check the list against the 2026 rules through the proper official resource. Mark any condition, threshold, or competition-only restriction. Confirm whether an existing TUE covers the exact substance, route, dose, frequency, and validity period. Plan renewal before expiration.

Share the result with the clinician and pharmacist. Keep an accessible copy when traveling. Repeat the review before competition and whenever treatment changes. This process protects health while making anti-doping compliance auditable.

References#

1. WADA 2026 Prohibited List
2. World Anti-Doping Code
3. International Standard for Therapeutic Use Exemptions
4. WADA Prohibited List athlete resource
5. Global DRO
6. USADA Supplement Connect